Isentress shows efficacy in treatment-naive HIV
This article was originally published in Scrip
Executive Summary
Merck & Co's first-in-class HIV integrase inhibitor, Isentress (raltegravir), can reduce viral load to undetectable levels with a responder rate comparable with that of efavirenz (a standard of care) in treatment-naive HIV patients, new Phase III data show. The results were presented at the recent joint Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America in Washington, DC.